biogen idec oncology
changing paradigms for the treatment of lymphoid malignancies
Co-chairs: A. Hagenbeek (Amsterdam, NL) and K.R. Rai (New York, USA)

Part I: Choosing the right treatment option in follicular lymphoma: the role of novel agents in the rituximab ERA

Current standard of care for indolent follicular lymphomas: is there any benefit to watch and wait?
R. Marcus (London, GB)

Does immediate treatment upon diagnosis affect outcome?
C. Thieblemont (Paris, FR)

New agents on the horizon for the treatment of lymphoid malignancies
G. Morgan (London, GB)

Biologics and antibody therapies in the settings of relapsed/refractory or first-line follicular lymphoma
M. Czuczman (Buffalo, USA)

Interactive discussion session

Part II: Controversies in the management of chronic lymphocytic leukemia (CLL)

Case presentations
K.R. Rai (New York, USA)

Case 1: Indolent CLL
Case 2: Aggressive form of CLL

CLL: what is the best course of action?
Moderator: K.R. Rai (New York, USA)

Chemotherapy, immunochemotherapy, or watch and wait for CLL: who benefits?
S. O’Brien (Houston, USA)

The relevance of novel biologics or dendritic cell vaccines for CLL
A. Nathwani (London, GB)